BioSpace News Archive

Digital compass. Business strategic explorer, Vision crisis, Mission path, Agency creative, Digital strategy, Market decision, Achievement strategy, Financial stock, Company vision concepts

Policy

FDA taps prior knowledge to expedite cell and gene therapy development

A year of significant policy change at the FDA brought momentum and scrutiny into the new year. As 2026 gets underway, biopharma companies are responding to sweeping vaccine changes while concerns surface about the politicization of the agency.

June 3, 2026

·

12 min read

·

BioSpace Editorial Staff

Full 3d poster art collage of anonym people wear armor two soldiers stand america china flag battle confrontation trade war.

NextGen

Facing pressure from China, BioSpace’s NextGen biotech leaders say: ‘Bring it on’

From Chinese innovation to AI, biotech CEOs are being hit with challenges at a breakneck pace. Three leaders from BioSpace’s NextGen Class of 2026 told us about the issues keeping them up at night.

June 3, 2026

·

6 min read

·

Annalee Armstrong

China

No longer a bargain pool, Chinese biotechs command higher premiums

Deal dynamics between Chinese biotechs and global pharma companies are changing fast, with the biotechs seeking higher upfront payments and the Big Pharmas seeking more expansive platform deals.

June 3, 2026

·

5 min read

·

Leslie Zhen Liang

RNA editing

Lilly targets kidney disease with Ascidian’s RNA exon editors for up to $1.9B

For an investment of up to $1.9 billion, Eli Lilly will be able to use Ascidian Therapeutics’ platform that removes mutated exons from mRNA molecules, avoiding the expression of disease-causing proteins.

June 3, 2026

·

2 min read

·

Tristan Manalac

Press Releases

Moonlight Therapeutics Initiates Phase I Clinical Trial (SURVEYOR) of MOON101 for Peanut Allergy

June 3, 2026

·

4 min read

Press Releases

Sanofi Chooses Snowflake to Accelerate its AI-Powered Drug Development